32 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
20 Jul 23
Interim TORREY OLE Update and PROSERA Phase 3 Design July 2023
7:50am
of effect in Phase 3 target population Attractive safety profile for chronic treatment Regulatory feedback supportive of single registrational study … chronic treatment in PAH patients Reports of cough diminish as patients get used to DPI Vast majority of patients have reached and maintained 90mg BID
8-K
EX-99.2
GOSS
Gossamer Bio Inc
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
, and PCP’s; 2019 AER = annualized severe exacerbation rate
TITAN Phase 2 Study in Chronic Rhinosinusitis – Topline Results TITAN: 16-week, Phase 2 … study in patients with chronic rhinosinusitis (CRS), both with and without polyps, randomized 97 patients to GB001 40 mg or placebo Study failed
8-K
EX-99.1
ouhgg3
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
8hpyxv4o mdf
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
qikewu5rfl5q
11 Aug 20
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
4:30pm
424B5
mpbwtas7nu 4h
19 May 20
Prospectus supplement for primary offering
5:11pm
424B5
xh9gdccymgcz
19 May 20
Prospectus supplement for primary offering
5:08pm
424B5
c5gfa8v
18 May 20
Prospectus supplement for primary offering
4:16pm
424B5
ldv8gkga5tw
18 May 20
Prospectus supplement for primary offering
4:11pm
8-K
EX-99.1
olp88er05i1o jc2a5u
12 May 20
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
4:18pm
8-K
EX-99.1
azz88 n0endi4e
24 Mar 20
Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
8:45am
8-K
EX-99.1
111dgwnoqh
12 Nov 19
Gossamer Bio Announces Third Quarter 2019 Financial Results
4:10pm